Omeros (NASDAQ:OMER) VP Peter Cancelmo Sells 25,000 Shares of Stock

Omeros Corporation (NASDAQ:OMER) VP Peter Cancelmo sold 25,000 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $18.65, for a total value of $466,250.00. Following the completion of the transaction, the vice president owned 200 shares in the company, valued at approximately $3,730. The trade was a 99.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Omeros Stock Performance

Shares of NASDAQ OMER opened at $18.75 on Wednesday. The stock’s 50-day simple moving average is $12.98 and its 200-day simple moving average is $12.14. The firm has a market capitalization of $1.36 billion, a PE ratio of 14.65 and a beta of 2.60. Omeros Corporation has a fifty-two week low of $3.94 and a fifty-two week high of $19.65.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. On average, sell-side analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omeros

A number of institutional investors have recently modified their holdings of the business. State of Wyoming acquired a new stake in Omeros during the 4th quarter worth $25,000. Caitong International Asset Management Co. Ltd purchased a new position in Omeros during the 4th quarter worth $33,000. Assetmark Inc. acquired a new position in Omeros in the first quarter valued at $38,000. Arax Advisory Partners increased its stake in Omeros by 56.4% in the fourth quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 1,894 shares during the period. Finally, International Assets Investment Management LLC raised its holdings in shares of Omeros by 16.0% in the first quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 800 shares during the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

OMER has been the topic of several research analyst reports. Zacks Research lowered shares of Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Weiss Ratings upgraded shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and an average target price of $38.00.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.